Initial research will be focusing on patients with multidrug-resistant, chronic infections associated with cystic fibrosis, organ transplantation, and implantable hardware (e.g. pacemakers joint replacements, etc.).
IPATH is currently working to launch the first NIH-funded phage therapy clinical trial within the National Institute of Allergy and Infectious Diseases (NIAID) Antibiotic Resistance Leadership Group (ARLG). Dr. Robert Schooley will serve as the Co-Primary Investigator, with initial site locations at IPATH, UC San Francisco and other ARLG clinical trial sites. This single-dose pilot study will focus on cystic fibrosis patients that are shedding Pseudomonas aeruginosa in expectorated sputum.
Burkholderia Patient Registry and Phage Library
In 2020, Dr. Saima Aslam was awarded a two-year grant, from the Cystic Fibrosis Foundation to create a Burkholderia-specific patient registry and lytic phage library. She is collaborating with the University of Pittsburgh Medical Center; University of Toronto; Duke University; Cleveland Clinic; Emory University; Université de Montréal; Vancouver General Hospital; Mayo Clinic, Rochester; University of Pennsylvania and Hadassah Medical Center to register Burkholderia-infected cystic fibrosis and lung transplant patients, and attempt to find matching phages against the patients' Burkholderia strains.
Methicillin-resistant Staphylococcus aureus (MRSA) Phage Library
Dr. David Pride was awarded a 2-year grant in 2020, from Emily's Entourage (a non-profit organization that accelerates research and drug development for cystic fibrosis). This funding will be used to create a well-characterized anti-MRSA phage library. Dr. Pride hopes to use this phage library to treat lung infections in future patients with cystic fibrosis.
For a list of recent publications by IPATH faculty, please see our Scientific Reports page.